A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia

NCT01812642 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: JNJ-37822681
OTHER: Placebo

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.